Evidence map›Paper›PMID 24910709›Full record

ArticleFuture virology2014

Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor

Olga Lihoradova, Tetsuro Ikegami

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. A Look intoViruses · 2021
    Review
  4. Review
  5. Article
  6. Rift Valley fever: current challenges and future prospects.Research and reports in tropical medicine · 2016
    Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Olga LihoradovaDepartment of Pathology, University of Texas Medical Branch, MMNP3.206D, 301 University Blvd. Galveston, TX 77555-0436, USA.
Tetsuro IkegamiDepartment of Pathology, University of Texas Medical Branch, MMNP3.206D, 301 University Blvd. Galveston, TX 77555-0436, USA ; Sealy Center for Vaccine Development, The University of Texas Medical Branch, Galveston, TX, USA ; Center for Biodefense & Emerging Infectious Diseases, The University of Texas Medical Branch, Galveston, TX, USA.
The University of Texas Medical Branch at Galveston · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8M
Reverse genetics to develop a second generation Rift Valley fever vaccineR01AI087643 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI IKEGAMI, TETSURO · 2011 to 2015
$1.9M
NIAID NIH HHS R01 AI087643NIAID NIH HHS UC7 AI094660
6 · The paper itself

Abstract

Rift Valley fever (RVF) is a mosquito-borne zoonotic disease characterized by a high rate of abortion in ruminants, and febrile illness, hemorrhagic fever, retinitis and encephalitis in humans. RVF is caused by the RVF virus (RVFV), belonging to the genus

Indexed as

MP-12NSsPhlebovirusRift Valley fever virusvaccine

Identifiers

PMID24910709
PMCPMC4043376
OpenAlexW2128450346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.